FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114563054> ?p ?o ?g. }

• W2114563054 endingPage "934" @default.
• W2114563054 startingPage "934" @default.
• W2114563054 abstract "To evaluate the efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibody (TNF-alpha MAb) in the treatment of patients with sepsis syndrome.Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.A total of 31 hospitals in the United States and Canada.There were 994 patients with sepsis syndrome enrolled in this clinical trial, and 971 patients were infused with the study drug.Patients were prospectively stratified into shock or nonshock groups and then randomized to receive a single infusion of 15 mg/kg of TNF-alpha MAb, 7.5 mg/kg of TNF-alpha MAb, or placebo. Patients received standard aggressive medical and surgical care during the 28-day postinfusion period.Twenty-eight-day all-cause mortality.The distribution of variables describing demographics, organ system dysfunction or failure, preinfusion Acute Physiology and Chronic Health Evaluation II score, number of organs failing at baseline, initial sites of infection, infecting microorganisms, antimicrobials used, and initial invasive procedures was similar among patients in the TNF-alpha MAb and placebo treatment arms. Among all infused patients, there was no difference in all-cause mortality in patients who received placebo as compared with those who received TNF-alpha MAb. In septic patients with shock (n = 478), there was a trend toward a reduction in all-cause mortality, which was most evident 3 days after infusion: 25 of 162 patients treated with 15 mg/kg of TNF-alpha MAb died, 22 of 156 patients treated with 7.5 mg/kg of TNF-alpha MAb died, and 44 of 160 patients in the placebo group died (15 mg/kg: 44% reduction vs placebo, P = .01; 7.5 mg/kg: 48.7% reduction vs placebo, P = .004). At day 28, the reduction in mortality for shock patients was not significant for either dose of TNF-alpha MAb relative to placebo (15 mg/kg, 61 deaths among 162 patients [37.7% mortality]; 7.5 mg/kg, 59 deaths among 156 patients [37.8% mortality]; placebo, 73 deaths among 160 patients [45.6% mortality]; P = .20 for 7.5 mg/kg and P = .15 for 15 mg/kg). Serious adverse events were reported in 4.6% of all infused patients. No immediate hypersensitivity allergic reactions due to TNF-alpha MAb were reported. Serum sickness-like reactions were seen in 2.5% of patients receiving TNF-alpha MAb.There was no decrease in mortality between placebo and TNF-alpha MAb in all infused patients. In septic shock patients who received TNF-alpha MAb, a significant reduction in mortality was present 3 days after infusion. Although a trend toward reduced mortality continued at 28 days following treatment with TNF-alpha MAb, the difference in mortality among shock patients treated with placebo or TNF-alpha MAb was not significant." @default.
• W2114563054 created "2016-06-24" @default.
• W2114563054 creator A5014333112 @default.
• W2114563054 creator A5029052230 @default.
• W2114563054 creator A5042697024 @default.
• W2114563054 creator A5052021118 @default.
• W2114563054 creator A5063505202 @default.
• W2114563054 creator A5064102787 @default.
• W2114563054 creator A5065540263 @default.
• W2114563054 creator A5073531000 @default.
• W2114563054 creator A5077828570 @default.
• W2114563054 creator A5086902938 @default.
• W2114563054 date "1995-03-22" @default.
• W2114563054 modified "2023-10-05" @default.
• W2114563054 title "Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome" @default.
• W2114563054 cites W1884955980 @default.
• W2114563054 cites W1934337364 @default.
• W2114563054 cites W1981003900 @default.
• W2114563054 cites W1989586079 @default.
• W2114563054 cites W2000421482 @default.
• W2114563054 cites W2001541164 @default.
• W2114563054 cites W2011291552 @default.
• W2114563054 cites W2031873118 @default.
• W2114563054 cites W2038434279 @default.
• W2114563054 cites W2039602526 @default.
• W2114563054 cites W2039967982 @default.
• W2114563054 cites W2045010042 @default.
• W2114563054 cites W2059707463 @default.
• W2114563054 cites W2062715532 @default.
• W2114563054 cites W2073188818 @default.
• W2114563054 cites W2073740655 @default.
• W2114563054 cites W2075023013 @default.
• W2114563054 cites W2075369004 @default.
• W2114563054 cites W2076452720 @default.
• W2114563054 cites W2093816949 @default.
• W2114563054 cites W2112875552 @default.
• W2114563054 cites W2133191409 @default.
• W2114563054 cites W2144509548 @default.
• W2114563054 cites W2148860016 @default.
• W2114563054 cites W2180812281 @default.
• W2114563054 cites W2296003737 @default.
• W2114563054 cites W2336770370 @default.
• W2114563054 cites W2343608432 @default.
• W2114563054 cites W2395767845 @default.
• W2114563054 cites W2414473958 @default.
• W2114563054 cites W2468848272 @default.
• W2114563054 cites W2107978811 @default.
• W2114563054 cites W2149506289 @default.
• W2114563054 doi "https://doi.org/10.1001/jama.1995.03520360048038" @default.
• W2114563054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7884952" @default.
• W2114563054 hasPublicationYear "1995" @default.
• W2114563054 type Work @default.
• W2114563054 sameAs 2114563054 @default.
• W2114563054 citedByCount "665" @default.
• W2114563054 countsByYear W21145630542012 @default.
• W2114563054 countsByYear W21145630542013 @default.
• W2114563054 countsByYear W21145630542014 @default.
• W2114563054 countsByYear W21145630542015 @default.
• W2114563054 countsByYear W21145630542016 @default.
• W2114563054 countsByYear W21145630542017 @default.
• W2114563054 countsByYear W21145630542018 @default.
• W2114563054 countsByYear W21145630542019 @default.
• W2114563054 countsByYear W21145630542020 @default.
• W2114563054 countsByYear W21145630542021 @default.
• W2114563054 countsByYear W21145630542022 @default.
• W2114563054 countsByYear W21145630542023 @default.
• W2114563054 crossrefType "journal-article" @default.
• W2114563054 hasAuthorship W2114563054A5014333112 @default.
• W2114563054 hasAuthorship W2114563054A5029052230 @default.
• W2114563054 hasAuthorship W2114563054A5042697024 @default.
• W2114563054 hasAuthorship W2114563054A5052021118 @default.
• W2114563054 hasAuthorship W2114563054A5063505202 @default.
• W2114563054 hasAuthorship W2114563054A5064102787 @default.
• W2114563054 hasAuthorship W2114563054A5065540263 @default.
• W2114563054 hasAuthorship W2114563054A5073531000 @default.
• W2114563054 hasAuthorship W2114563054A5077828570 @default.
• W2114563054 hasAuthorship W2114563054A5086902938 @default.
• W2114563054 hasConcept C126322002 @default.
• W2114563054 hasConcept C141071460 @default.
• W2114563054 hasConcept C142724271 @default.
• W2114563054 hasConcept C168563851 @default.
• W2114563054 hasConcept C204787440 @default.
• W2114563054 hasConcept C27081682 @default.
• W2114563054 hasConcept C2775965419 @default.
• W2114563054 hasConcept C2777628635 @default.
• W2114563054 hasConcept C2778384902 @default.
• W2114563054 hasConcept C2992435398 @default.
• W2114563054 hasConcept C535046627 @default.
• W2114563054 hasConcept C71924100 @default.
• W2114563054 hasConcept C90924648 @default.
• W2114563054 hasConceptScore W2114563054C126322002 @default.
• W2114563054 hasConceptScore W2114563054C141071460 @default.
• W2114563054 hasConceptScore W2114563054C142724271 @default.
• W2114563054 hasConceptScore W2114563054C168563851 @default.
• W2114563054 hasConceptScore W2114563054C204787440 @default.
• W2114563054 hasConceptScore W2114563054C27081682 @default.
• W2114563054 hasConceptScore W2114563054C2775965419 @default.
• W2114563054 hasConceptScore W2114563054C2777628635 @default.

• next